[Form 3] CASI Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
CASI Pharmaceuticals, Inc. Chief Operating Officer Wang Chunhua filed an initial ownership report detailing existing option holdings in CASI ordinary shares. The filing lists multiple options to buy shares at exercise prices of $1.93, $2.67 and $5.78, with expirations ranging from 2028 through 2034.
According to a footnote, all of these options are fully vested and exercisable as of the date of the form, meaning they can already be converted into ordinary shares subject to their terms. The report reflects holdings rather than new purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
14 transactions reported
Mixed
14 txns
Insider
Wang Chunhua
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 20,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Option grant: 20,000 shares at $1.93
Option grant: 7,500 shares at $2.67
Option grant: 30,000 shares at $5.78
+1 more
4 metrics
Option grant
20,000 shares at $1.93
Option to buy CASI ordinary shares, expiration in 2028
Option grant
7,500 shares at $2.67
Option to buy CASI ordinary shares, expiration in 2034
Option grant
30,000 shares at $5.78
Option to buy CASI ordinary shares, expiration in 2034
Fully vested options
All reported options
Footnote states options are fully vested and exercisable
Key Terms
Form 3, Option (right to buy, exercise price, fully vested and exercisable
4 terms
Form 3 regulatory
"Chief Operating Officer Wang Chunhua filed an initial ownership report on Form 3."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Option (right to buy financial
"The filing lists each security title as "Option (right to buy)" over ordinary shares."
exercise price financial
"Several option positions show an exercise price of $1.93, $2.67 or $5.78 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested and exercisable financial
"A footnote explains the options are fully vested and exercisable as of the form date."
